SMPDL3A: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: SMPDL3A

NCBI ID: G10924

SMPDL3A

SMPDL3A: A Potential Drug Target and Biomarker for Neurological Disorders

SMPDL3A (YR36GH4.1) is a protein that is expressed in various tissues of the body, including the brain. It is a key regulator of the spatial order of neural cell types, and is known for its role in the development and progression of various neurological disorders.

SMPDL3A has been identified as a potential drug target for a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the formation of aggregates of neurotransmitters, which can lead to the symptoms associated with the disorders.

SMPDL3A has been shown to be involved in the regulation of the trafficking of neurotransmitter-producing neurons, which are responsible for transmitting signals in the brain. Studies have shown that SMPDL3A plays a role in the delivery of dopamine, a neurotransmitter that is involved in mood, motivation, and pleasure.

In addition to its role in neurotransmitter trafficking, SMPDL3A is also involved in the regulation of the formation of synapses, which are the structures that allow neurons to communicate with each other. Studies have shown that SMPDL3A is involved in the formation of synapses in the brain, and that its absence can lead to the formation of abnormally large synapses that can disrupt neural communication.

The role of SMPDL3A in neurological disorders is also being investigated for its potential as a drug target. Studies have shown that blocking the activity of SMPDL3A has the potential to treat a variety of neurological disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential as a drug target, SMPDL3A is also of interest as a biomarker for the development of neurological disorders. The spatial order of neural cell types is a critical factor in the development of these disorders, and changes in the spatial order of cell types have been observed in the brains of individuals with these conditions.

SMPDL3A has been shown to be involved in the regulation of the spatial order of neural cell types, and is known for its role in the development and progression of these disorders. Its potential as a drug target and as a biomarker for the development of neurological disorders make it an attractive target for future research.

In conclusion, SMPDL3A is a protein that is expressed in various tissues of the body, including the brain, and is known for its role in the development and progression of various neurological disorders. Its potential as a drug target and as a biomarker for the development of these disorders make it an attractive target for future research. Further studies are needed to fully understand the role of SMPDL3A in neurological disorders and its potential as a drug and biomarker.

Protein Name: Sphingomyelin Phosphodiesterase Acid Like 3A

Functions: Has in vitro nucleotide phosphodiesterase activity with nucleoside triphosphates, such as ATP (PubMed:25288789, PubMed:26783088). Has in vitro activity with p-nitrophenyl-TMP (PubMed:25288789). Has lower activity with nucleoside diphosphates, and no activity with nucleoside monophosphates (PubMed:25288789, PubMed:26783088). Has in vitro activity with CDP-choline, giving rise to CMP and phosphocholine. Has in vitro activity with CDP-ethanolamine (PubMed:26783088). Does not have sphingomyelin phosphodiesterase activity (PubMed:25288789, PubMed:26783088)

The "SMPDL3A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMPDL3A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets